A reappraisal of the clinical efficacy of nebulized flunisolide in pediatric asthma: The Italian experience

Allergy and Asthma Proceedings

Volumn 28, Issue 6, 2007, Pages 671-687

  Kantar, Ahmad ^a   Mroueh, Salman ^b   Fiocchi, Alessandro ^c  

^a Centro Per la Cura e la Riabilitazione dell'Asma Infantile   (Italy)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c Melloni Hospital   (Italy)

Author keywords

Asthma; Clinical; Flunisolide; Nebulization; Pediatric; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ANTIASTHMATIC AGENT; BECLOMETASONE; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; DRUG DERIVATIVE; FLUNISOLIDE; FLUOCINOLONE ACETONIDE;

AEROSOL; ARTICLE; ASTHMA; CHILD; DRUG ADMINISTRATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; ITALY; NEBULIZER;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AEROSOLS; ANTI-ASTHMATIC AGENTS; ASTHMA; BECLOMETHASONE; BRONCHODILATOR AGENTS; BUDESONIDE; CHILD; DRUG ADMINISTRATION SCHEDULE; FLUOCINOLONE ACETONIDE; HUMANS; ITALY; NEBULIZERS AND VAPORIZERS;

EID: 38349095658     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/aap.2007.28.2979     Document Type: Article

References (103)

1. Foucard T. Aggressive treatment of childhood asthma with local steroids. Good or bad? Allergy 51:367-371, 1996.
2. Bush A. Asthma in the child under five. Br J Hosp Med 55:110-114, 1996.
3. Szefler SJ. Clinical need for nebulized corticosteroid. J Allergy Clin Immunol 104:5162-5168, 1999.
4. Pedersen S, and O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 52:51-834, 1997.
5. Clavenna A, Rossi E, Berti A, et al. (ARNO Working Group). Inappropriate use of anti-asthmatic drugs in the Italian paediatric population. Eur J Clin Pharmacol 59:565-569, 2003.
6. Chaplin M, Rooks W, Swenson EW, et al. Flunisolide metabolism and dynamic of a metabolite. Clin Pharma Ther 27:402-413, 1980.
7. Shapiro GG, Izu AE, Furukawa CT, et al. Short-term double-blind evaluation of flunisolide aerosol for steroid-dependent asthmatic children and adolescents. Chest 80:671-675, 1981.
8. Gillman SA, Anolik R, Schenkel E, et al. One-year trial on safety and normal linear growth with flunisolide HFA in children with asthma. Clin Pediatr (Phila) 41:333-340, 2002.
9. Waugh J, and Goa KL. Flunisolide HFA. Am J Respir Med 1:369-372, 2002.
10. Corren J, and Tashkin DP. Evaluation of efficacy and safety of flunisolide hydrofluoroalkane for the treatment of asthma. Clin Ther 25:776-798, 2003.
11. Shafazand S, and Colice G. Flunisolide HFA for the treatment of asthma: An old friend reformulated. Expert Opin Pharmacother 5:1163-1173, 2004.
12. Szefler SJ. Phramacodynamic and pharmacokinetics of budesonide: A new nebulized corticosteroid. J Allergy Clin Immunol 104:S175-S183, 1999.
13. Hvizdos KM, and Jarvis B. Budesonide inhalation suspension. A review of its use in infants, children and adults with inflammatory respiratory disorders. Drugs 60:1141-1178, 2000.
14. Hill JM. Nebulised corticosteroids in the treatment of patients with asthma. Thorax 54:661-663, 1999.
15. Todd GRG, and Jennifer H. Nebulised Fluticasone. Thorax 55:345c, 2000.
16. O'Callaghan C, and Barry P. Asthma drug delivery devices for children. BMJ 320:664, 2000.
17. O'Callaghan C, and Barry PW. How to choose delivery devices for asthma. Arch Dis Child 82:185-187, 2000.
18. Boe J, Dennis JH, and O'Driscoll BR. European Respiratory Society nebulizer guidelines: Clinical aspects. Eur Respir Rev 10,76:495-583, 2000.
19. Smye SW. The physics of corticosteroid nebulization. Eur Respir Rev 7:184-188, 1997.
20. Dennis JH, and Nerbrink O. New nebulizer technology. In Drug Delivery to the Lung. Bisgaard H, O'Callaghan C, and Smaldone GC (Eds.). New York: Marcel Dekker, 162:303-336, 2002.
21. Niven RW. Atomization and nebulizers. In Inhalation Aerosol: Physical and Biological Basis for Therapy. Hickey AJ (Ed.). New York: Marcel Dekker, 273-312, 1996.
22. O'Callaghan C, and Barry PW. The science of nebulised drug delivery. Thorax 52:331-344, 1997.
23. Knoch M, and Sommer E. Jet nebulizer design and function. Eur Respir Rev 72:183-186, 2000.
24. Dalby RN, Tiano SL, and Hickey AJ. Medical devices for the delivery of therapeutic aerosols to the lungs. In Inhalation Aerosol: Physical and Biological Basis for Therapy. Hickey AJ (Ed.). New York: Marcel Dekker, 441-473, 1996.
25. Nikander K, Turpeinem M, and Wollmer P. The conventional ultrasonic nebulizer proved inefficient in nebulizing a suspension. J Aerosol Med 12:47-53, 1999.
26. Wood JA, Wilson RS, and Bray C. Changes in salbutamol concentration in the reservoir solution of a jet nebulizer. Br J Dis Chest 80:164-169, 1986.
27. McCallion ON, Taylor KM, Thomas M, et al. Nebulization of fluids of different physicochemical properties with air-jet and ultrasonic nebulizers. Pharm Res 12:1682-1688, 1995.
28. Barry PW, and O'Callaghan C. Drug output from nebulizers is dependent on the method of measurement. Eur Respir J 12: 463-466, 1998.
29. Davis SS. Physico-chemical studies on aerosol solutions for drug delivery: I-Water-propylene glycol systems. Inter J Pharm 1:71-78, 1978.
30. Itoh H, Smaldone GC, Swift DL, et al. Mechanisms of aerosol deposition in a nasal model. J Aerosol Sci 16:529-534, 1985.
31. Collis GG, Cole CH, and Le Souef PN. Dilution of nebulised aerosols by air entrainment in children. Lancet 336:341-343, 1990.
32. Iies R, Lister P, and Edmunds AT. Crying significantly reduces absorption of aerosolised drug in infants. Arch Dis Child 81:163-165, 1999.
33. Altiere RJ, and Thompson DC. Physiology and pharmacology of the airways. In Inhalation Aerosol: Physical and Biological Basis for Therapy. Hickey AJ (Ed.). New York: Marcel Dekker, 85-137, 1996.
34. Grotberg JB. Pulmonary flow and transport phenomena. Ann Rev Fluid Mech 26:529-571, 1994.
35. O'Callaghan C, and Barry P. Delivering inhaled corticosteroids to patients. If side effects are important, why are we so ignorant of the dose inhaled? BMJ 318:410-411, 1999.
36. O'Callaghan C, White J, Barry P, et al. Analysis of the output of beclomethasone dipropionate from different nebulisers. Riv Ital Pediatr (IJP) 26:821-824, 2000.
37. O'Callaghan C, White J, Jackson J, et al. The output of flunisolide from different nebulisers. J Pharm Pharmacol 54:565-569, 2002.
38. O'Callaghan C, White J, Jackson J, et al. Delivery of nebulised budesonide is affected by nebulizer type and breathing pattern. J Pharm Pharmacol 57:787-790, 2005.
39. Stocks J, and Hislop AA. Structure and function of the respiratory system: Developmental aspects and their relevance to aerosol therapy. In Drug Delivery to the Lung. Bisgaard H, O'Callaghan C, and Smaldone GC (Eds.). New York: Marcel Dekker, 162:47-104, 2002.
40. Smaldone GC. Smart nebulizers. Respir Care 47:1434-1444, 2002.
41. Edsbäcker S. Uptake, retention, and biotransformation of corticosteroids in the lung and airways. In Inhaled Steroids in Asthma. Optimizing Effects in the Airways. Schleimer RP, O'Byrne PM, Szefler SJ, and Brattsand R (Eds.). New York: Marcel Dekker, 163:213-246, 2002.
42. Heyder J, and Svartengren MU. Basic principles of particle behavior in human respiratory tract. In Drug Delivery to the Lung. Bisgaard H, O'Callaghan C, and Smaldone GC (Eds). New York: Marcel Dekker, 162:21-45, 2002.
43. Zanen P, and Laube BL. Targeting the lungs with therapeutic aerosols. In Drug Delivery to the Lung. Bisgaard H, O'Callaghan C, and Smaldone GC (Eds). New York: Marcel Dekker, 162:211-268, 2002.
44. Wechsler EM, and Israel E. How pharmacogenomics will play a role in the management of asthma. Am J Respir Crit Care Med 172:12-18, 2005.
45. Weiss ST, Lake SL, Silverman ES, et al. Asthma steroid pharmacogenetics: A study strategy to identify replicated treatment response. Proc Am Thorac Soc 1:364-367, 2004.
46. Tantisira KG, Lake S, Silvermen ES, et al. Corticosteroid pharmacogenetics: Association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet 13:1353-1359, 2004.
47. Kelly HW. Establishing a therapeutic index for the inhaled corticosteroids: Part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids. J Allergy Clin Immunol 102:536-851, 1998.
48. Johnson M. Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. J Allergy Clin Immunol 97:169-176, 1996.
49. Brattsand R. What factor determine anti-inflammatory activity and selectivity of inhaled steroids? Eur Respir Rev 7:356-361, 1997.
50. Johnson M. Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol 101:S434-S439, 1998.
51. Cave A, Arlett P, and Lee E. Inhaled and nasal corticosteroids: Factors affecting the risks of systemic adverse effects. Pharmacol Ther 83:153-179, 1999.
52. Barnes PJ, Pedersen S, and Busse WW. Efficacy and safety of inhaled corticosteroids: New developments. Am J Respir Crit Care Med 157:S1-S51, 1998.
53. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy. Arch Intern Med 159:941-955, 1999.
54. Kelly HW. Pharmaceutical characteristics that influence the clinical efficacy of inhaled corticosteroids. Ann Allergy Asthma Immunol 91:326-334, 2003.
55. Kelly HW. Comparative potency and clinical efficacy of inhaled corticosteroids. Respir Care Clin N Am 5:537-553, 1999.
56. Derendorf H. Phramacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety. Respir Med 91:22-28, 1997.
57. Kelly HW. Comparison of inhaled corticosteroids. Ann Pharmacother 32:220-232, 1998.
58. Kelly HW. Pharmacology of inhaled glucocorticoids: Comparative properties. Immunol Allergy Clin N Am 19:725-738, 1999.
59. LeVan TD, Babin EA, Yamamura HI, et al. Pharmacological characterization of glucocorticoid receptors in human bronchial epithelial cells. Biochem Pharamcol 57:1003-1009, 1999.
60. Hochhaus G, Möllmann H, Derendorf H, et al. Pharmacokinetic/ pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model. J Clin Pharmacol 37:881-892, 1997.
61. Spahn JD, Leung DY, Surs W, et al. Reduced glucocorticoid binding affinity in asthma is related to ongoing allergic inflammation. Am J Respir Crit Care Med 151:1709-1714, 1995.
62. Meyer T, Carlstedt-Duke J, and Starr D. A weak TATA box is a prerequisite for glucocorticoid-dependent repression of the osteocalcin gene. J Biol Chem 272:30709-30714, 1997.
63. Jaffuel D, Demoly P, Gougat C, et al. Transcriptional potencies of inhaled glucocorticoids. Am J Respir Crit Care Med 162:57-63, 2000.
64. Rinderknecht J, Shapiro L, Krauthammer M, et al. Accelerated clearance of small solutes from the lungs in interstitial lung disease. Am Rev Respir Dis 121:105-117, 1980.
65. Dickens GR, Wermeling DP, Matheny CJ, et al. Pharmacokinetics of flunisolide administrated via metered dose inhaler with and without a spacer device and following oral administration. Ann Allergy Asthma Immunol 84:528-532, 2000.
66. Chaplin MD, Cooper WC, Segre EJ, et al. Correlation of flunisolide plasma levels to eosinopenic response in humans. J Allergy Clin Immunol 65:445-453, 1980.
67. Derendorf H, Hochhaus G, Meibohm H, et al. Pharmacokinetics and phramcodynamics of inhaled corticosteroids. J Allergy Clin Immunol 101:S440-S446, 1998.
68. Derendorf H, Hochhaus G, Krishnaswamii et al. Systemic disposition and effects of inhaled corticosteroids. In Inhaled Steroids in Asthma. Optimizing Effects in the Airways. Schleimer RP, O'Byrne PM, Szefler SJ, and Brattsand R (Eds.). New York: Marcel Dekker, 163:247-272, 2002.
69. Mackie AE, Ventresca GP, Fuller RW, et al. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Br J Clin Pharmacol 41:539-542, 1996.
70. Thorsson L, Edsbacker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler p-MDI. Eur Respir J 7:1839-1844, 1994.
71. Derendorf H, Hochhaus G, Rohatagi S, et al. Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Phramacol 35:302-305, 1995.
72. Tomlinson RV, Runkel R, Chaplin MD, et al. In vitro studies on the binding of cloprednol to human plasma proteins. J steroid Biochem 16:75-80, 1982.
73. Ryrfeldt A, Andresson P, Edsbacker S, et al. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur Respir Dis 122:86-95, 1982.
74. Daley-Yates PT, Tournant J, and Kunka RL. Comparison of the systemic availability of fluticasone propionate in healthy volunteers and patients with asthma. Clin Pharmacokinet 39:39-45, 2000.
75. Thorsson L, Dahlström L, Edsbacker S, et al. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol 43:155-161, 1997.
76. Harter JG, Reddy WJ, and Thorn GW. Studies on an intermittent corticosteroid dosage regimen. N Engl J Med 269:591-596, 1963.
77. Falcoz C, Kirby S, Smith J, et al. pharmacokinetics and systemic exposure of inhaled beclomethasone dipropionate. Eur Respir J 9:162S, 1996.
78. Wiedmann TS, Bhatia R, and Wattenberg LW. Drug solubilization in lung surfactant. J Control Release 65:43-47, 2000.
79. Hallman M. Recycling of surfactant: A review of human amniotic fluid as a source of surfactant for treatment of respiratory distress syndrome. Rev Perinat Med 6:197-226, 1989.
80. Möllmann H, Derendorf H, Earth J, et al. Pharmacokinetic/ pharmacodynamic evaluation of systemic effects of flunisolide after inhalation. J Clin Pharmacol 37:893-903, 1997.
81. Meibohm B, Hochhaus G, Möllmann H, et al. Absorption profiles of inhaled corticosteroids. Pharm Res 14:5141, 1997.
82. Hochberg RB, Bandy L, Ponticorvo, et al. Detection in bovine adrenal cortex of a lipoidal substance that yields pregnenolone upon treatment with alkali. Proc Natl Acad Sci USA 74:941-945, 1977.
83. Miller-Larsson A, Mattsson H, Hjertberg E, et al. Reversible fatty acid conjugation of budesonide: Novel mechanism for prolonged retention of topically applied steroid in airway tissue. Drug Metab Dispos 26:623-630, 1998.
84. Hochberg RB. Biological esterification of steroids. Endocr Rev 19:331-348, 1998.
85. Miller-Larsson A, Jansson P, Runström A, et al. Prolonged airway activity and improved selectivity of budesonide possibly due to esterification. Am J Respir Crit Care Med 162:1455-1461, 2000.
86. Piacentini GL, Sette L, Peroni DG, et al. Double-blind evaluation of effectiveness and safety of flunisolide aerosol for treatment of bronchial asthma in children. Allergy 45:612-616, 1990.
87. de Benedicitis FM, Martinati LC, Solinas LF, et al. Neblized flunisolide in infants and young children with asthma: A pilot study. Pediatr Pulmonol 21:310-315, 1996.
88. Allen ED, Whitaker ER, and Ryu G. Six-week trial of nebulized flunisolide nasal spray: Efficacy in young children with moderately severe asthma. Pediatr Pulmonol 24:397-405, 1997.
89. Armenio L, Cherti GF, Spadavecchia E, et al. Esperienza pediatrica sull'uso del flunisolide aerosol nella patologia flogistica-ostruttiva delle vie aeree. Indagine policentrica. Riv Broncopneumo Ped I:1-8, 1989.
90. Amato GM, Barcellona R, Travia A, et al. Valutazione clinica controllata del flunisolide soluzione inalante in bambini con asma cronico. Studio multicentrico. Riv Broncopneumo Ped 2:41-48, 1990.
91. Eisenberg J. Use of nebulized flunisolide in infants and children with asthma and bronchopulmonary dysplasia (BPD). Am Rev Respir Dis 141:A899, 1990.
92. Chin T, and Nussbaum E. Use of nebulized flunisolide in pediatric asthma. Am Rev Respir Dis 143.-624A, 1991.
93. Longo G, Poli F, and Strinati R. Valutazione clinica del flunisolide somministrato per aerosol in pazienti asmatici di età prescolare. Riform Med 106:1-6, 1991.
94. König P, Shatley M, Levine C, et al. Clinical observations of nebulized flunisolide in infants and young children with asthma and bronchopulmonary dysplasia. Pediatr Pulmonol 13:209-214, 1992.
95. Strinati R, Poli F, Longo G, et al. Valutazione comparativa di flunisolide e beclometasone dipropionato somministrati per aerosol in pazienti con asma persistente. Ped Oggi 9:151-156, 1989.
96. Terzano C, Barkai L, and Cremonesi G. Corticosteroids administered by nebulization to children with bronchial asthma. Adv Ther 18:253-260, 2001.
97. Brutsche MH, Brutsche IC, Munawar M, et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet 356:556-561, 2000.
98. Giorgi PL, Oggiano N, Biraghi M, et al. Effect of high doses of inhaled flunisolide on hypothalamic-pituitary-adrenal axis function in children with asthma. Curr Ther Res 49:778-783, 1991.
99. Giorgi PL, Oggiano N, Kantar A, et al. Bone metabolism in children with asthma treated with nebulized flunisolide: A multicenter Italian study. Curr Ther Res 59:896-908, 1998.
100. Taylor DR, and Hancox RJ. Interaction between corticosteroids and β agonists. Thorax 55:595-602, 2000.
101. Lampa E, Filippelli A, Pirozzi A, et al. Antitracheobronchospastic interaction in vitro and in vivo between salbutamol and flunisolide. Drugs Exptl Clin Res 11:653-658, 1985.
102. La Rosa M, Francesco G, Musarra I, et al. Double-blind comparative study of inhaled flunisolide and flunisolide plus salbutamol in bronchial asthma in children. Curr Ther Res 50:56-61, 1991.
103. Fiocchi A, Sala M, Marangione P, et al. Studio clinico per la valutazione di efficacia e tollerabilità del flunisolide per via aerosolica dell'asma cronico del bambino. Riv Pedaitr Prev Soc 42:301-306, 1992.